Skip to main content
Equibles
NXL logo

NXL · Nexalin Technology, Inc.

Track NXL — free

Use NXL with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$6.04 -0.76 (-11.14%) At close · Sep 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has evaluated these conditions and concluded that the Company does not currently have sufficient cash and cash equivalents to fund its anticipated operating requirements for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. Accordingly, substantial doubt exists about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$4.99M
Shares
734,547

NXL metrics

40 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.80
Market cap
$4.99M

Price action

19 metrics
Price change (1W)
—
Price change (30D)
-5.9%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
734,547

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
23.0×
reciprocal yield 4.3%
P / book
3.3
reciprocal yield 30.4%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-180.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
86.2%
Operating margin
-4,202.5%
Trailing 12 months
Net margin
-4,139.4%
Gross profit (TTM)
$187,097
Operating profit (TTM)
−$9.13M
Net income (TTM)
−$8.99M
Trailing 12 months
Diluted EPS (TTM)
$-14.10
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-10.34

Growth

11 metrics
Revenue growth YoY
-82.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$217,155
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+34.5%
Year over year · more shares
Revenue CAGR (3Y)
-38.9%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-591.6%
Return on assets
-299.2%
Debt / equity
—
Current ratio
1.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
1.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$1.00M
Total assets
$3.00M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.13M
Capital expenditures (TTM)
—
R&D (TTM)
$1.36M
SG&A (TTM)
$4.15M
Stock compensation (TTM)
$2.80M
R&D / revenue
627.4%
Stock compensation / revenue
1,290.0%

Ownership (13F)

3 metrics
13F filers
20
13F filer change QoQ
-3
Institutional ownership
3.9%

Short interest

3 metrics
Short interest
1.6%
Latest settlement · 3.0 days to cover
Days to cover
3.0d
Short-squeeze score
57 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1527352 CUSIP 65345B201 13F (30d) 18 filings 18 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)